ArticleOncoTargets and therapy2022

An Innovative Site-Specific Anti-HER2 Antibody-Drug Conjugate with High Homogeneity and Improved Therapeutic Index.

Xiwu Hui et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.